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ABSTRACT
EFFECTS OF MALFORMED OR ABSENT VALVES TO LYMPHATIC FLUID
TRANSPORT AND LYMPHEDEMA IN VIVO IN MICE
SEPTEMBER 2017
AKSHAY S. PUJARI
BACHELOR OF ENGINEERING, SHIVAJI UNIVERSITY, INDIA
MASTER OF SCIENCE, UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Juan M. Jiménez

Lymph is primarily composed of fluid and proteins from the blood circulatory
system that drain into the space surrounding cells, interstitial space. From the interstitial
space, the fluid enters and circulates in the lymphatic system until it is delivered into the
venous system. In contrast to the blood circulatory system, the lymphatic system lacks a
central pumping organ dictating the predominant driving pressure and velocity of lymph.
Transport of lymph via capillaries, pre-collecting and collecting lymphatic vessels relies
on the synergy between pressure gradients, local tissue motion, valves and lymphatic
vessel contractility. The direction of lymph transport is regulated by bicuspid valves
distributed throughout pre-collecting and collecting lymphatic vessels.
Effective transport of lymph into the venous system is of prime importance.
Disruption of lymph transport, because of impaired lymphatic function, reduced numbers
of vessels or valvular insufficiencies can have severe health consequences, including
lymphedema for which current clinical therapies are not curative. The lymphatic valves
are usually bicuspid, however, congenital malformations in the valve such as single

vi

leaflet valve formation and arrested lymphatic valve development are observed and can
cause lymphedema.
Here we employ 4-week-old mice to study the effects of valves and malformed
valves on lymph transport shedding light into some of the potentially underlying
consequences of lymphedema. Polyethylene glycol (PEG) coated latex particles were
injected into the inguinal lymph node of anesthetized mice.

Particle displacement

measurements through efferent lymphatic vessels yielded velocity, wall shear stress,
vorticity and strain of the efferent lymph flow field carrying lymph from subdermal
inguinal lymph nodes. Lymphatic vessel endothelial Prox1 green fluorescent protein
(GFP) marker enabled the detection of lymphatic vessel walls and valves. Flow field,
flow velocity, flow rate, velocity profiles, wall shear stress, vorticity and strain values
were compared in regions downstream of normal and malformed valves in two wild type
mice. A Clec2-deficient mouse, which experiences lymphatic development defects and is
used as a lymphedema model, was employed to further elucidate the lymphatic valves on
transport.
The absence of centralized pumping yields highly variable lymphatic flow cycles
varying from one to fifteen seconds. The presence of lymphatic valves introduces
boundary conditions that yield spatial and temporal flow gradients increasing the degree
of complexity of lymph transport. The valves dictate the trajectory of the particles and
promote the formation of recirculation zones. Even in the presence of valves, lymph flow
commonly reverses. Congenital defects like a single leaflet valve lowers the lymph flow
efficiency and promotes higher wall shear stress regions. Furthermore, the absence of
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functional valves in the Clec2-deficient mouse not displaying lymphedema yielded lymph
flow lacking the pulsatility that characterizes normal lymphatic flow.
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CHAPTER 1
INTRODUCTION AND BACKGROUND

1.1 The Lymphatic System
The circulatory system is comprised of two separate systems: the cardiovascular
system, which distributes blood, and the lymphatic system, which circulates lymph. The
blood circulatory system is a closed system, whereas the lymphatic system is one-way
open system.
Arterial blood carries oxygen, nutrients, and hormones for the cells. Oxygenated
blood travels arteries, arterioles and capillaries to perfuse tissues throughout the body.
During this process fluid, primarily plasma, travels between cells as interstitial fluid and
it delivers its nourishing products to the cells. This fluid along with cellular waste is
transported via the lymphatic system into the venous system.
One of the primary roles of the lymphatic system is to transport this excess
interstitial fluid back to the blood circulation via the thoracic duct into the venous system
[1], [2]. Along with the excess interstitial fluid, excessive proteins and waste are
transported back to the circulation. The lymphatic system also acts as a conduit for
immune cells and facilitates the immune response. Lymph nodes across the network filter
the interstitial flow and provide immunity against bacteria, viruses and waste. Thus,
along with being an integral part of the circulatory system, the lymphatic system is also
an integral part of the immune system.
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1.1.1 Anatomy and Physiology
Unlike the cardiovascular system, the lymphatics do not have a centralized
pumping organ. The lymphatic system is composed of a network of vessels, termed as
lymphatics, lymph nodes and lymphoid organs. Anatomically, the vessels of the lymphatic
system are sub-divided into the initial lymphatics, pre-collecting lymphatics, collecting
lymphatics and organs such as nodes. The origins of the lymphatic system, known as the
initial lymphatics, are dispersed throughout the capillary network of the mesentery. The walls
of the initial lymphatics are usually not contractile and only lined with endothelial cells.

All tissues connected perfused by the cardiovascular system have supporting
lymphatics to serve as its drainage system, with the notable exception of bone marrow
and the central nervous system [3]. Lymphatic capillaries are tiny, thin-walled blindended vessels composed of a single monolayer of non-fenestrated lymphatic endothelial
cells (LEC) and are present in all tissues in the interstitial spaces [4]. The lymphatic
capillaries are strategically placed and anatomically constructed to permit a continuous
and rapid removal of transient interstitial fluids and plasma proteins from the interstitium.
The endothelial cells are arranged in an overlapping pattern and each cell is attached to
nearby tissue by anchoring filaments to keep them from collapsing under higher fluid
pressures [5]. The anchoring filaments are mainly composed of the emilin-1 and fibrillin
proteins, which may attach to the LECs via molecules such as αvβ3 integrin [6], [7].
When pressure in the interstitium is greater than in the capillaries, the flap-like
endothelial cells separate slightly and interstitial fluid enters the lymphatic capillary. In
contrast, if pressure is greater inside the lymphatic capillary, the LECs adhere closely, to
prevent retrograde flow. The fluid entered in the capillaries is now termed as lymph
2

which is a clear fluid with an approximate density of 1000 kgm-3 [8] and the dynamic
viscosity ranging between 1.5 × 10-3 and 2.2 × 10-3 cP [9].
The lymph travels from the capillaries into the pre-collecting lymphatics. The precollecting lymphatics connect the lymphatic capillaries to the collecting vessels. They
contain bicuspid one-way valves; however, the distribution of valves is irregular and even
comprise occasional single leaflet valves [10]. Smooth muscle cells are observed in the
pre-collecting and larger lymphatic vessels. The presence of smooth muscle cells
decreases vessel permeability in these vessels, while its absence enables fluid adsorption
in the initial lymphatics.

Figure 1: Organization of lymphatic vascular system [7]
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The collecting lymphatics deliver lymphatic fluid to the lymph nodes through
afferent vessels and drain the lymph away from the node through efferent lymph vessels.
The collecting lymphatic vessels connect with chains of lymph nodes that sieve and
monitor lymph to mount an immune response when necessary. The collecting lymphatics
differ from the capillaries and pre-collector vessels, especially in lumen diameter.
Intraluminal lymphatic valves are present primarily to ensure net antegrade flow. The
part of the vessel between two valves is known as a lymphangion. The lymphatics is
composed of a series of connected lymphangions.
Lymph propulsion is the outcome of contractions of the lymphangions and by
external motion of skeletal muscle, arteries and veins. In this manner, the lymph is
transported by pumping towards the venous system in the neck region [2]. Lymph from
the left side of the body, abdomen, and both lower limbs ends up in the thoracic duct, the
largest lymphatic vessel that runs alongside the aorta, and finally connects with the left
subclavian vein. Lymph from the right upper arm, thorax, and head is returned to the
right subclavian vein via the right lymphatic trunk [11]. In healthy adult individuals, the
lymphatic system returns as much as eight liters of interstitial fluid with 20–30 g of
protein per liter to the venous circulation every day [3]. The wall structure of these
vessels are similar to that of blood vessels and consists of three layers: the intima, media
and adventitia [12].
1. Intima: The inner layer of lymphatic vessels is composed of a single monolayer
of lymphatic endothelial cells (LEC), also known as the lymphatic endothelium.
The lymph is in direct contact with the endothelial cells. Lymphatic endothelium
is further discussed in detail in next sub-section.
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2. Media: Smooth muscle cells are arranged in a circular fashion around the
endothelium that help alter the lumen pressure by contracting and relaxing. The
activity of smooth muscles allows lymph vessels to slowly pump lymph fluid
through the body. Smooth muscle cells are absent in initial lymphatics. An
extensible protein called elastin enables reshaping of the vessel after contraction.
3. Adventitia: The outermost layer of the vessel is the adventitia, consisting of
fibrous tissue. It is primarily composed of collagen and serves to anchor the
lymph vessels to structures within the body for stability. Larger lymph vessels
have many more layers of adventitia than the smaller lymphatic vessels.
Adventitia is absent in initial and pre-collecting lymphatics.

The lymphatic vessels are comparable to blood vessels, however, structure of
smooth muscle, elastin and collagen networks in the lymphatic walls are not present in
blood vessels [13]. Blood vessel walls are not designed to contract spontaneously, since
the heart pumps the blood around the body. Blood vessels experience mainly radial
stresses [13]. The lymphatic walls actively pump the lymph which creates longitudinal as
well as radial stresses. The forces present in the cardiovascular system are much higher
than in the lymphatic system. Additionally, as the velocities in the lymphatic system are
much slower, the Reynolds numbers are significantly lower than in the cardiovascular
system.
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1.1.2 Lymphatic Endothelium
Lymphatic endothelial cells (LECs) originate from embryonic blood endothelial
cells (BECs) during embryogenesis. The hematopoietic signalling proteins SLP76 and
SYK are known to regulate blood and lymphatic vascular differentiation during
development [14]. The two endothelial cell types, therefore, share features such as flat
morphology, apico-basal polarity and certain common endothelial-specific proteins.
However, many phenotypic and genetic characteristics are unique for one or the other
vessel type and are routinely used to differentiate between blood and lymph vessels in
histological specimens and vascular biology. Recent studies have demonstrated that the
BECs and LECs represent differentiated cell lineages without evidence of any
interconversion between the distinguishing phenotypic properties [15].
The LECs are terminally differentiated cells distinct from blood vascular
endothelial cells [16]. This has enabled the discovery of lymphatic vascular-specific
molecules that are used for identification of lymphatic vessels in tissues, as well as for
finding targets for the specific induction or inhibition of lymphatic vessel growth in
pathological conditions [16], [17]. Blood vessels express plasmalemma vesicle associated
protein 1 (PV-1), endoglin, neuropilin-1 (NRP-1) and collagen IV [18]. Lymph vessels
on the other hand express markers such as podoplanin (PDPN), lymphatic endothelial
hyaluronan receptor-1 (LYVE-1) [19], vascular endothelial growth factor receptor-3
(VEGFR-3) and prospero related homeobox 1 (PROX-1) [18]. Among these, the
transcription factor PROX-1 is known to be the most specific lineage marker for LECs
[20] and for the downregulation of numerous BEC-specific genes [21]. LYVE-1
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expression remains high in lymphatic capillaries and decreases in collecting lymphatic
vessels [22].
ECs that line the lumen of blood and lymphatic vessels are exposed to mechanical
forces generated by fluid flow. The endothelium responds to shear stress through various
mechanosensitive pathways depending on the kind and the magnitude of shear stresses
(9). LECs exposed to shear stresses due to flow have shown upregulation in genes such as
FOXC2, GATA2, ITGA9 and CX37 during development and promote valve formation
[23]. PROX-1expression is not altered by lymphatic fluid shear forces. LYVE-1
expression is significantly downregulated.
Modulating shear stress through flow rate has been found to induce release of the
vasodilator nitric oxide (NO) in lymphatic vessels. As in blood vessels, the SMCs lining
the lymphatic vessels respond to changes in Ca2+ concentration, which generally alter
vessel contraction [24], [25]. NO acts at multiple points in the Ca2+ contraction pathway
to modulate Ca2+ release and uptake, as well as the enzymes responsible for force
production [26], [27]. Blocking or enhancing NO activity can dramatically affect
pumping behavior. Studies have investigated and revealed that NO release is driven by
upregulation of enzyme endothelial nitric oxide synthase (eNOS) in LECs.

NO

produced by eNOS in the vascular endothelium plays crucial roles in regulating
vascular tone and cellular proliferation. Another study has revealed the role of shear
stress in phosphorylation of eNOS, thus upregulating NO [28] .
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1.1.3 Lymphatic Valves
One of the main structural features of lymphatic vessels are their valves, which
are normally semilunar structures attached to opposite sides of the lymphatic
endothelium. Valves are present even in the blood circulatory system, but only in low
pressure venous circulation. They function similarly to lymphatic valves, however are
more dependent on skeletal muscle contractions. Lymphatic valves are found in larger
lymph vessels and collecting vessels and are absent in the initial lymphatics. The valves
serve to prevent retrograde flow during relaxation of the vessel wall and to promote net

forward flow [29]. Ideally, the pressure of lymph increases to a certain point due to
lymph volume or from smooth muscle contraction, the fluid will be pushed through the
valve into the next chamber of the vessel, lymphangion. As the pressure drops, the open
valve then closes so that the lymph fluid cannot flow backwards.
Lymphatic valves are composed of 2 intraluminal leaflets, each of which is
formed by two layers of LECs separated by an extracellular matrix–rich core [30].
Generally, the lymphatic valves are of the bicuspid type, regardless of the species [31].
However, up to five leaflet valves as well as single leaflet ones have been observed.
Studies have shown that smooth muscle cells (SMC) are absent from the valve leaflets
[8]. The lymphangions, thus, do not have the ability to contract in the valvular regions
due to absence of SMCs.
Studies have shown defects in valve formation due to certain genes such as
FOXC-2 and lymph flow during development. Valvular malformations can promote
lymphatic system dysfunctions which are discussed in detail in the next section [32].
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1.2 Lymphatic System Malfunction
Abnormal function of lymphatic vessels is important in multiple diseases
including inflammation and cancer. The lymphatic vessels contribute to a wide range of
human diseases such as inflammation, lymphatic insufficiency, obesity, hypertension and
metastasis platform for tumors [3]. Impaired lymphatic function, reduced numbers of
lymphatic vessels and valvular insufficiencies cause disruption of lymph transport [33].
The outcome of a disrupted lymphatic system is compromised lymph drainage. The
lymph is retained in the vessels and the interstitial sites, the ability to maintain fluid
balance and tissue homeostasis is compromised and immune function can be impaired.
This condition is one of the most common forms of lymphatic dysfunction and is coined
lymphedema.
The two major classifications of lymphedema are primary and secondary [34].
Primary lymphedema can be genetic or congenital and can be first noticed birth or it can
develop later in life during puberty or later. Unlike primary lymphedema, secondary
lymphedema is caused due to damage to collecting lymphatic vessels.
Although primary lymphedema is a rare condition, identification of the
underlying genetic causes has provided insight into the molecular mechanisms regulating
the development and function of the lymphatic vasculature. Insights into the molecular
and genetic mechanisms of lymphedema have been greatly enhanced over the last few
years [20]. This is mainly attributable to:
(1) the discovery of gene mutations in two different types of lymphedema,
(2) the identification of specific receptors on LECs
(3) the recent development of genetic mouse models for cutaneous lymphedema.
9

Two lymphangiogenic factors,

VEGF-C and VEGF-D, and their lymphatic

receptor VEGFR3 gene have been identified as a major cause of Milroy disease, which
causes lymphedema due to hypoplasia of lymphatic capillaries and is typically observed
at birth [3]. Primary lymphedema has been classified as Milroy disease when present at
birth (Milroy 1892), or as Meige disease, which develops predominantly after puberty
(Meige 1898). Both diseases are characterized by a combination of dilated lymphatic
capillaries and interstitial accumulation of lymph fluid leading to lymphedema. Mutations
in the transcription factor FOXC2 have been linked to lymphedema-distichiasis (LD)
characterized by late-onset lymphedema and varicose veins [35]. Previous studies of
FOXC2 mutant mice reveals that LD is due to loss of valves in the collecting vessels.
Similar results are observed in samples obtained from LD patients [21]. Heterozygous
missense mutations in α9 integrin (ITGA9) underlie congenital chylothorax in human
fetuses, recapitulating the results obtained by gene targeting in mice [36].
Dominant-negative mutations of the homeobox transcription factor SOX18 have
been linked with hypotrichosis-lymphedema-telangiectasia syndrome [37]. Mutations in
the NF-κB regulatory protein NEMO associate with a rare and complex syndrome
involving lymphedema [38] .
C-type lectin–like receptor 2 (CLEC2) deficiency in mice develop normal
lymphatic system, but the lymph flow is opposed by the backflow of blood from the
venous system as the result of a hemostatic defect [39]. C-type lectin–like receptor 2
(CLEC2) is a cell-surface receptor and is expressed by platelets. Previous studies have
reported the presence of lymph flow playing a central and broad role in the development
of collecting lymphatic vessels and valves [23]. CLEC2-deficient animals with reduced
10

lymph flow, thus, lack lymphatic valves, fail to remodel the primitive mesenteric
lymphatic plexus into a hierarchical collecting vessel network, and exhibit premature and
excess smooth muscle cell coverage of their collecting lymphatic vessels. CLEC2deficient mice can thus be used as lymphedema models [23].
Secondary lymphedema is acquired due to damage to the lymphatic vessels due to
surgery or from lymphatic filariasis [40], caused by a parasitic worm invading the
lymphatic system. Filariasis causes a complete and permanent disruption of lymphatic
transport, resulting in chronic lymphedema of the legs and genitals [41]. The onset of
filariasis is triggered by a filarial-specific inflammatory reaction that promotes the
production of VEGF, VEGF-C, and VEGF-D, which leads to persistent hyperplasia of
the lymphatic vessels [42]. Filariasis is the principal cause of lymphedema worldwide,
affecting approximately 100 million people [42]. Arm lymphedema is very common in
breast cancer patients as an outcome of node dissection during surgery [8].
Lymphedema is progressive and lifelong and very few treatments have been
proposed to restore flow and resolve the lymphedema. The treatment of lymphedema is
currently based on physiotherapy, compression garments, liposuction, and occasionally
surgery for manual lymphatic drainage, however, the longevity of the treatment is
unknown [43].

1.3 Vascular Fluid Dynamics
The Reynolds number, Re, is the ratio of the inertial fluid forces to viscous fluid
forces. At lower values of Reynolds number, the viscous forces dominate the fluid flow.
It has been noted that the Reynolds number in the collecting lymphatics is small due to
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the viscosity of the flow and the size of the vessels [44]. It has been assumed that lymph
is a Newtonian fluid and does not contain solid particles [45], [46]. In Newtonian fluids,
the viscous stresses are proportional to the local strain rate,
𝛾̇ = 𝑑𝑢/𝑑𝑟
where μ is the kinematic viscosity of the fluid, u is the tangential velocity component and
r is the radial spatial variable. Newton’s law for shear stress is given by:
𝑊𝑆𝑆 = 𝜇 ∗ 𝛾̇
𝑊𝑆𝑆 = 𝜇 ∗

𝑑𝑢
𝑑𝑟

Normal stresses due to fluid pressure are transferred to all vessel wall layers
(intima, media and adventitia). In contrast, shear stress is experienced by the cellular
inner layer, endothelium, in contact with the flowing fluid.

1.4 Objectives
Despite the importance of the lymphatic system in health and disease, it remains
overlooked in terms of research, especially compared with the blood circulatory system
[48], [49]. The study of the lymphatic system is still in its infancy. Studies of the uptake
and transport of drugs into the body via the intestinal lymphatic system have received
increasing attention in recent years. The effective transport of fluid in the lymphatic
system is important for preventing consequences such as lymphedema. It is essential that
we understand how various lymphatic diseases alter the vessel mechanical environment.
Improving our understanding of lymph fluid flow will enhance our knowledge on how
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lymphatic transport of waste, immune cells, and proteins around the body and potentially
develop new ways of treating lymphedema by understanding the origins of the disease.
The primary objective of this study is to compare the effects of single leaflet valve
malformation in wild type mouse to normal valves within the same animal as well as in
other wild type mouse. The single leaflet valve is hypothesized to affect the flow and
thus, effective lymph transport. This mouse serves as a model to study valvular
insufficiency and malformations that can potentially contribute to lymphedema.
Biological processes involving endothelial cells are often studied in vitro due to
the challenging nature of in vivo studies. However, characterizing the flow field
experienced by LECs in vivo is key to understanding how the lymphatic system functions
in normal and disease states.
One example where lymph fluid dynamics may be important is in cancer
metastasis. The lymphatic system is the metastatic route for various types of cancers.
Metastasis through lymphatic system is recognized to precede hematological spread in
many cancers including melanoma, breast, colon, lung and prostate cancers. The
lymphatics, thus, have the potential to play a large role in anticancer treatment [47].
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CHAPTER 2
EXPERIMENTAL SETUP

2.1 Experimental Summary
Four mice were anaesthetized using 2,2,2-Tribromoethanol (Sigma-Aldrich)
dissolved in tert-amyl alcohol (Sigma-Aldrich) (0.5 mg/g), and body temperature was
maintained at 37°C throughout experiment [23]. Ventral skin was peeled back to expose
an inguinal lymph node. The inguinal lymph nodes are located medial to the femoral vein
and under the cribriform fascia as shown in Figure 2.

Figure 2: Anaesthetized mouse with ventral skin peeled back exposing the inguinal
lymphatic nodes

Because the lymphatic network is filled from the periphery, it is difficult to
globally label lymph, thus, fluorescent particles were introduced in the lymphatics. The
inguinal lymph node was injected with 5 μl of FluoSpheres (1 μm beads, 580/605,
Invitrogen) diluted in sterile PBS for a concentration of 1 × 108 beads/ml. The beads were
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coated with Polyethylene Glycol (PEG), a hydrophilic molecule, to avoid binding of
particles to each other and to the vessel.
The efferent (post-nodal) lymphatic vessel was imaged for several minutes
immediately following bead injection under a dissecting microscope as shown in Figure
3. Lymphatic endothelial PROX1 green fluorescent protein (GFP) marker enabled
lymphatic vessel edge detection.

Figure 3: Anaesthetized mouse under a dissecting microscope. The efferent vessel to
inguinal lymphatic node was imaged.
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2.2 Image Acquisition
Fluorescent-based imaging techniques are commonly implemented in animal
research to overcome the poor contrast that is often inherent in biological imaging. Live
animal imaging was conducted as shown in Figure 3 using green and red fluorescence
and an Olympus MVX10 dissecting microscope. The mice employed expressed PROX1
green fluorescent protein in LECs. In contrast, the injected particle tracers fluoresced red.
Particle displacement through efferent lymphatic vessels was imaged for several minutes.
One of the primary challenges in imaging was the animal moving the plane of interest in
and out of focus due to breathing and other muscular movements.

2.3 Mice Specifications
Two four-week-old wild type mice were considered for the studying the effects of
single leaflet valve. Additional mouse cases involving a wild type mouse and a Clec2-/Mouse were imaged for further studies. The phenotype of each mouse is described in
Table 1. The weights of the mice varied from 14 to 25 grams.
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Table 1: Mice specifications. Mouse 1 (control) and Mouse 2 were considered for the
study
Case

Phenotype

Valves

Abbr.

MOUSE 1

Wild-Type

One normal bi-leaflet valve

WT

MOUSE 2

Wild-Type

Two bi-leaflet valves,
One uni-leaflet malformed valve

MV

MOUSE 3

Wild-Type

One normal bi-leaflet valve

WT2

MOUSE 4

Clec2Deficient

Abnormal non-functional valve

Clec2-/-

Figure 4: Image acquired from WT Mouse and MV Mouse. The green fluorescence
depicts the labeling of the lymphatic endothelium by PROX-1 GFP. The particles
stained in red dye are seen in red.
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Figure 5: Image acquired from WT2 Mouse and Clec2-/- Mouse. The green
fluorescence depicts the labeling of the lymphatic endothelium by PROX-1 GFP.
The particles stained in red dye are seen in red.

Table 2: Mice image specifications
Case

Image Size
(μm)
361 × 85

Frame Rate
(fps)
30

Flow Direction

MOUSE 1

Image Size
(pixels)
1301 × 305

MOUSE 2

1391 × 181

386 × 50

30

Right to Left

MOUSE 3

1181 × 246

328 × 68

30

Left to Right

MOUSE 4

1911 × 841

530 × 233

30

Left to Right
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Right to Left

2.4 Immunohistochemistry Experiments
Based on few previous studies and as discussed in the previous chapter, eNOS
was found be upregulated in the LECs subjected to higher flow. It was hypothesized that
the region downstream of valves would be subjected to higher flow velocities and higher
WSS. To verify this hypothesis, immunohistochemistry (IHC) experiments were
performed on mouse tissues to study the expression of eNOS in the lymphatics.
IHC was performed on mesenteric gut acquired from 3 to 10 days old wild-type
(WT) mice. Greater adipose tissue in the mesentery of older animals increases the degree
of complexity when imaging the lymphatics, thus mice younger than 10 days were
selected.

Mesenteric gut was dissected carefully from mice, thus, preserving the

morphology and the lymphatics surrounding the mesentery. All samples were washed
three times with PBS (Life Technologies) and fixed with 5% formalin (Fisher). The
tissues were then washed with PBS along with 0.1% Triton-X (Sigma-Aldrich) (PBS-Tx)
to promote permeabilization. To minimize nonspecific binding of the primary and
secondary antibodies, blocking solution casein (Life Technologies) was used for 30-min
at room temperature followed by adding primary antibodies eNOS (Santa-Cruz
Biotechnology) and PROX1 (Abcam) diluted 1:120 in blocking solution. The tissues
were then incubated overnight at 4-degree Celsius. This was followed by three washes in
PBS-Tx and overnight incubation with the secondary antibodies that were fluorescently
tagged - Alexa Fluor 488 chicken anti-goat (Life Technologies), diluted 1:250; Alexa
Fluor 488 donkey anti rabbit (Life Technologies), diluted 1:250. The samples were then
washed with PBS-Tx in a dark room to avoid photobleaching. The gut was then carefully
emptied using forceps to remove partially digested food which is auto-fluorescent under a
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dissecting microscope in a dark room. Smaller samples of tissues were mounted on glass
slides using vectashield mounting media (Sigma-Aldrich) and cover slips, and examined
with a confocal microscope. Imaging was performed at 20x and PROX1-GFP enabled the
detection of lymphatics.
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CHAPTER 3
ANALYSIS METHODS

3.1 Image Processing
Particle displacement through efferent lymphatic vessels was imaged with a
dissecting microscope as discussed in Chapter 2. Twenty-five seconds of data were
selected from each recording with 30 frames per second imaging a single plane for a total
of 750 fluorescent images.
A custom denoising program was written for detecting and removing artifacts and
stabilizing images affected by breathing of the animal, muscle activity, amongst other
causes. The first image in the series served as the reference image to stabilize all other
images in the series. First, all images were cross-correlated with the first image to obtain
a coarse displacement for each image with relation to the first image in the series. The
coarse displacement data was then used to align the images with respect to the first image
in the series. A finer image displacement calculation was conducted using the stabilized
series and the Template Matching and Slice Alignment ImageJ Plugin. A third run was
conducted in MATLAB incorporating the two separate displacement datasets. With these
displacement datasets, the power spectral density was calculated revealing the power
present in the signal. Peaks in the signal coincide with animal breathing rate, muscle
twitching and other physiologically related movements (Figure 6 and Figure 7).
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Figure 6: Power Spectrum Density for the WT Mouse (Blue) and MV Mouse (Red)

Figure 7: Power Spectrum Density for WT2 Mouse (Blue) and Clec2–/– Mouse (Red)

ImageJ (National Institutes of Health, Bethesda, MD) and MATLAB
(MathWorks, Natick, MA) were used for post processing to retrieve data from images
post hoc such as vessel diameter, particle velocity, etc. as discussed in subsequent
sections.
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3.2 Vessel Edge Detection
We define the process of partitioning an image into multiple segments of pixels as
image segmentation. All the pixels in a region are similar with respect to some
characteristic or computed property, such as color, intensity, or texture. These objects can
be processed or analyzed for the extraction of quantitative information. Live animal data
can be noisy and consequently difficult to segment accurately.
Edge detection includes a variety of mathematical methods that aim at identifying
points in an image at which the image brightness changes sharply or has discontinuities.
The points at which image brightness changes sharply are typically organized into a set of
curved line segments termed edges. The discontinuities in an image are found by
calculating the first and/or second order derivatives of an image. A multi-step algorithm –
Canny-Deriche edge detector [48] was implemented to identify the set of bright pixels
from the green channel representing the vessel edge. The green channel in the images
corresponded to the expression of endothelial Prox1-GFP.
The pixels representing vessel edge were detected by Canny-Deriche algorithm
and were stored in file for each frame for each of the mouse cases. Each pixel had an x
and y coordinate value. The number of pixels stored was dependent on the brightness of
the edge and clarity of the image. Lesser number of pixels were stored for out of focus
frames.
MATLAB was used to analyze the pixel data. A local regression technique was
implemented to identify the vessel edge curve. The local curve fitting technique helps
identify accurately the shape of the vessel. However, the fitting varied in successive
frames. To account for sudden changes in the vessel geometry in successive frames,
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spatial and temporal smoothing was performed on the fitted curves. Each frame now had
two sets of x and y coordinates which represented the top and bottom curves of the
lymphatic vessel (Figure 8).
The vessel diameter was calculated as the distance between top and bottom curves
of the vessel after considering the angle of orientation of the lymphangion. The diameter,
D, was computed at every point of the vessel for all the frames.

Figure 8: Curves showing the outcome of edge detection procedure on a green
channel image for MV Mouse case
3.3 Particle Tracking
Particle tracking velocimetry is a technique to measure velocity of particles that
are resident in a fluid. This technique is based on Lagrangian approach which involves
tracking individual particles. The local particle tracking is based on comparison of
successive frames. To calculate the individual particle shift, sub-regions much smaller
than the images are analysed from two different successive images acquired Δt time apart
within that specific interrogation window area.
Several computational tools are available to assist with detection of shapes or
particles and to evaluate the trajectories of the identified shapes in a sequence of images.
Particle tracking tools assume the target particles to be brighter than the local
background. Image quality and frame rate significantly affect the results of automated
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particle tracking. Higher frame rate values ensure the distance travelled by a particle is
lower between the frames.

3.3.1 Challenges
A major challenge of particle tracking is the fact that segmented objects at
different time points may have no relationship between consecutive frames. The steps for
successful tracking are:
(i)

To correctly identify the objects that should be part of the same track.

(ii)

To accurately join them as part of a track.

(iii)

To precisely track the objects position even if on occasion the object may
disappear or reappear.

The detection of particles in vivo in a two-dimensional focal plane makes particle
tracking complex because the breathing of the animals renders the plane of interest out of
focus and blurry. Computationally, blurry particles are labelled as particles with larger
diameters. Thus, particle tracking tools fail to identify a particle in subsequent frames if it
changes in size and brightness and the software assigns different labels to the same
particle in different frames. Particle density and clustering of particles present further
challenges in unique particle identification. Also, some particles closer to the vessel wall
tend to be stationary, while particles away from the wall flow over the stationary
particles.
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3.3.2 Tracking Tools Used
ImarisTrack (Bitplane, Belfast, UK) software for two-dimensional images was
used for initial particle detection and tracking (Figure 9). Due to computer RAM
limitations, entire sequence of images could not be imported into the software and the
image sets were into shorter image sequences. Statistical data such as particle
coordinates, track identification number, span of the tracks was extracted from
ImarisTrack. A custom MATLAB code was written to combine entire tracking data by
merging tracks for each mouse case.
However, due to challenges in tracking as discussed previously, the tracking of
particles was not accurate. Particle coordinates from ImarisTrack were converted to .mdf
files that could be read by the MTrackJ plugin for ImageJ. The MTrackJ plugin offered
greater manual control for manual tracking and was used for interactive manual trajectory
inspection, modification and creation.

Figure 9: Sample image depicting the location of detected particles in a frame in the
WT Mouse
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3.3.3 Particle Velocity
A unique identification number was allotted to each particle after manual tracking
was performed in mTrackJ. The velocity of the particle was computed using the particle
coordinates from two consecutive frames and calculate as follows.
ut = Δx/Δt
vt = Δy/Δt
Based on directionality of the flow of the particles, the sign convention was
defined for each case (Table 3). Forward flow depicts the flow of lymph moving towards
veins from the interstitium.
Table 3: Velocity sign convention
Forward moving particle

positive

+u

Backward moving particle

negative

-u

Upward moving particle

positive

+v

Downward moving particle

negative

-v

3.4 Region of Interests
Presence of valves and lack of pumping organ promote variable flow fields in the
lymphatics. Retrograde flow adds to the degree of complexity within the flow. The flow
fields vary temporally within a single lymphangion as well. In order to compare
lymphatic fluid flow within different regions of the lymphatic vessels, segments of equal
width were defined at different regions of the vessels as shown in Figure 10 and Figure
11. Figure 10 is for the control mouse with a single bi-leaflet valve (WT) and Figure 11
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for a mouse with one uni-leaflet and two bi-leaflet (MV). Since SMCs are present around
each lymphangion, it is expected that the vessel contraction is maximum at the center of
the lymphangions. Hence, the center was defined based on the maximum contraction of
the vessel within that lymphangion. The distance of the segment downstream from the
valves was kept at a constant ratio based on the length of the lymphangion. Fluid and
vessel properties were analyzed in the defined segments.

Figure 10: Defined segments in WT Mouse

Figure 11: Defined segments in MV Mouse
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3.5 Particle Data Interpolation
The number of particles flowing inside the vessel varied for each mouse case.
Hence, a custom function was generated to interpolate the particle displacement in order
to generate a uniformly distributed vector field. Zero velocity no-slip condition was
considered at the vessel wall and valve surfaces. MATLAB function griddata for twodimensional non-uniformly spaced was used to interpolate the values of velocity
components on a gridded mesh. Triangulation-based cubic interpolation method was
implemented [49] for second order continuity.

Figure 12: Location of actual particles in MV Mouse at a random time point

Figure 13: Interpolated pseudo-particles in same frame in MV Mouse

Figure 12 shows the coordinates (x, y) of actual particles at an instant within the
Mouse 2 vessel and Figure 13 shows the uniformly space coordinates inside the vessel.
The values of velocity, vorticity, shear strain and normal strain were then calculated at all
points in the interpolated data.
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CHAPTER 4
RESULTS AND DISCUSSION

4.1 Overview
The data presented in this chapter are results after image analysis for two mice.
WT Mouse and MV Mouse were used to study the effects of valve malformation. The
comparison of valves or regions was based on calculations in segments defined in section
3.4. Vessel contraction, fluid velocity, development of velocity profiles within a flow
cycle, variable trajectory of particles, flow fields changes within a flow cycle, wall shear
stress, vorticity and strain were calculated and compared. A lymphatic universal flow
function is proposed.

4.2 Vessel Contraction Over Time
Differences in vessel diameter were observed in each animal. The value of
diameter changed from lymphangion to lymphangion within the same animal as well.
Due to heterogeneity in vessel size and, normalization techniques were implemented for
comparison of parameters in different animals.
Figure 14 shows the movement of vessel or the change in vessel diameter at
defined segments in WT Mouse and MV Mouse. Vessel diameter is expressed in terms of
non-dimensional diameter (D/Dmax), wherein D/Dmax = 1, represents the maximum vessel
diameter in that particular segment. Maximum vessel diameter implies vessel in dilated
form and smaller values indicate contracted vessel due to the SMCs and other factors.
Elastin helps contracted vessel to retain its shape.
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In diameter analysis of WT and MV Mice cases, the maximum contraction was
observed at the center of the lymphangion and no contraction was observed in the
valvular regions. This confirms that the absence of SMCs yield no vessel contraction.in
the valve region of collecting lymphatics. However, the contraction at the center segment
of the lymphangions is greatest (Figure 14a) for WT Mouse, wherein gray and black
curves depict center of two neighboring lymphangions. The segment immediately
downstream of the uni-leaflet valve was found to contract less in comparison to the
segment downstream of bi-leaflet valve in MV Mouse (Figure 14b).
The contraction pattern observed in three cases was different and no correlation
was found in the correlation study. The maximum vessel contraction observed was
approximately 9% and 16 % in WT and MV, respectively. The contraction differences in
comparison to different cases and even within the same animal in different lymphangions
shows the heterogeneity of the lymphatic system.
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Figure 14: (a) Changes in vessel diameter (D) in WT Mouse at three segments for 25
seconds. Red (solid) curve depicts the segment downstream of the normal bi-leaflet
valve, gray (dashed) and black (double-dashed) curves represent the segments at
center of the lymphangions; (b) Changes in vessel diameter (D) in MV Mouse at
three segments for 25 seconds. Red (solid) curve depicts the segment downstream of
the bi-leaflet valve, green (dashed) curve depicts the segment downstream of the
uni-leaflet valve and black (double-dashed) curve represents the segment at center
of the lymphangion
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4.3 Fluid Velocity
Particle velocity of each tracked particle was computed in MATLAB as discussed
in previous chapter. Radial velocity profile was plotted based on the streamwise velocity
u values of each particle within the segment. The particles within the segment were
assumed to be positioned at the center plane of the segment, the plane at which diameter
was calculated. Based on the particle velocities, velocity values were plotted and marked
as solid dots in Figure 15. Higher order spline curve fits were used for curve
representations of the velocity profile as shown in Figure 15.

Figure 15: Sample velocity profile. The solid points on the curve represent the actual
streamwise velocity value (u) of the particles in the segment. The red curve
represents a spline curve fit.

The aggregate velocity U in the plane was computed by integration of fitted
velocity curve profile. This technique was implemented to calculate U for all the defined
segments at each of 750-time points spanning 25 seconds.
Linear flow rate of the fluid Q* was defined as the product of velocity u to the
diameter D of the segment.
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Q* = u*D
The changes in the values of Q* were compared for multiple segments and is
shown in Figure 16. The values of Q* are proportional to the values of U by the factor of
vessel diameter. However due to challenges in particle tracking and presence of lesser
number of particles at an instantaneous time points, U values could not be estimated. Q*
values represented in Figure 16 show the curve fit of Q* values from the actual data. As
seen in the figure, the velocity of the fluid is observed to have negative values as well.
The negative values of U or Q* implies retrograde flow within that segment. The flow in
MV was observed to reverse even in the presence of valves – both normal and
malformed. The flow was observed to be reversing in the valvular segment as well which
showcases the presence of inter-lymphangion retrograde flow even in presence of valves.
The differences in magnitudes of the flow rate varied for different cases and it is just an
account of heterogeneity of the lymphatic system.

34

Figure 16: Changes in flow rate (Q*) at three segments for 25 seconds in (a) WT
Mouse - Red (solid) curve depicts the segment downstream of the normal bi-leaflet
valve, gray (dashed) and black (double-dashed) curves represent the segment at
center of the lymphangions; (b) MV Mouse - Red (solid) curve depicts the segment
downstream of the bi-leaflet valve, green (dashed) curve depicts the segment
downstream of the uni-leaflet valve and black (double-dashed) curve represents the
segment at center of the lymphangion
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4.4 Flow Cycles
Individual flow cycles were selected starting with first point that flow reverses
until it reverses again. The temporal span of flow cycles Tcycle varies for each mouse and
varies differently for each segment in a mouse vessel. This highlights the heterogeneity in
lymphatic flow. The absence of a pumping organ is the primary contributing factor for
this irregularity.
Different flow cycles were identified and Tcycle was found to be different in all the
cycles. For comparison of cycles in different segments and different mouse cases, a new
term (τ) was defined. τ rescales all the flow cycles from 0 to 1. Zero value of τ defines the
start of flow cycle (retrograde flow) and one defines the end of flow cycle.

𝐓 − 𝐦𝐢𝐧(𝐓𝐜𝐲𝐜𝐥𝐞)

τ = 𝐦𝐚𝐱 (𝐓𝐜𝐲𝐜𝐥𝐞) − 𝐦𝐢𝐧(𝐓𝐜𝐲𝐜𝐥𝐞)

One cycle was selected for both WT and MV Mice. The values of velocity u over
the span of this cycle can be seen in Figure 17. The differences in time of each time cycle
was overcome by changing the time scale from time in seconds to τ as defined
previously. Segment 3 from WT Mouse was not considered in this analysis due to lesser
number of particles in the segment and particles being out of focus. For both cases, the
antegrade flow direction dominated implying a net forward flow in both cases.
To study the localized effects in each segment over the cycle, we calculated the
velocity profiles (as discussed earlier) at five values of τ: 0.0, 0.25, 0.5, 0.75, 1.0 for each
cycle. The diameter was normalized to compare the nature of the velocity profile. The
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diameter of vessel changes over the cycle span for both mice as seen in previous section.
The diameter was normalized as follows:
𝑫 − 𝒎𝒊𝒏(𝑫)

D* = 𝒎𝒂𝒙 (𝑫) − 𝒎𝒊𝒏(𝑫)
where D* ranges from 0 to 1. A value of 1 represents the largest diameter for that segment
and corresponding to maximal vessel dilation. A value of zero for D* implies the vessel
walls are touching. The velocity profiles for five time points were plotted with respect to
D* for two cases and is shown in Figure 18.

Figure 17: One flow cycle at segments. (a) WT Mouse - Red (solid) curve depicts the
segment downstream of the normal bi-leaflet valve, black (double-dashed) curve
represents the segment at center of the lymphangion, segment at the center of
upstream lymphangion was ignored in this study due to absence of sufficient
particles in the focal plane in that segment. (b) MV Mouse - Red (solid) curve
depicts the segment downstream of the bi-leaflet valve, green (dashed) curve depicts
the segment downstream of the uni-leaflet valve and black (double-dashed) curve
represents the segment at center of the lymphangion
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Figure 18: Velocity profiles at the segments at five time points (τ = 0.0, 0.25, 0.5,
0.75, 1.0) within one cycle. The solid points show the actual u value of the particles.
The solid curve represents spline fit. (a) WT Mouse - Red curve depicts the segment
downstream of the normal bi-leaflet valve, black curve represents the segment at
center of the lymphangion; (b) MV Mouse - Red curve depicts the segment
downstream of the bi-leaflet valve, green curve depicts the segment downstream of
the uni-leaflet valve and black curve represents the segment at center of the
lymphangion

At τ = 0, as seen in Figure 17, the flow is transitioning from forward flow to
backward flow. The velocity values are closer to zero in all segments. The velocity
profile is more parabolic at τ = 0.5. The profile becomes further parabolic at the valvular
segment (Red curve) in WT Mouse at τ = 0.75. The region downstream of the normal
valve (Red curve) in MV Mouse shows a more parabolic profile in comparison to region
downstream of malformed valve (Green curve).
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4.5 Flow Cycle Universality
Figure 19 shows two flow cycles each for the three segments in WT Mouse. Thus,
the total number of flow cycles plotted are six. Curve peaks were found to properly shift
the curves such that (t/tcycle) = 0 corresponds to the maximum peak of each curve. The
maximum u value of multiple peaks (Umax) differed in amplitude. Interestingly, the
lowest cycle-Umax was 50% of the highest value of Umax. Thus, adding another key finding
to the observation of heterogeneity of lymphatic flow cycles. Figure 19a shows u/Umax
plotted on t/tcycle scale and peaks shifted to zero for WT.
Similarly, three flow cycles each for three segments in MV were plotted using the
same methods described before (Figure 19b). Thus, 9 flow cycles were considered for
MV Mouse for this study.
The u values for all the cycles for each mouse were averaged such that one curve
was generated representing the average of all the flow cycles. Analysis was performed on
these two averaged curves based on methodology shown in Figure 20. The time scale t
was rescaled to t/t0, where t0 is difference in time from peak (of u value: Umax) to time
when the amplitude u0 is 50% of the amplitude u0 as shown in Figure 20. Velocity u was
normalized on scale of from 0 to 1 as follows:
𝐮 − 𝐦𝐢𝐧(𝐮)

u* = 𝐦𝐚𝐱 (𝐮) − 𝐦𝐢𝐧(𝐮) =

𝐮 − 𝐦𝐢𝐧(𝐮)
𝒖𝟎

A value of zero on the normalized velocity scale can also imply retrograde flow.
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Figure 19: Multiple flow cycles (u/Umax) within one animal at different segments
plotted on a normalized time scale (t/tcycle), curve peaks shifted such that (t/tcycle) = 0.
(a) Six flow cycles from three segments in WT Mouse; (b) Nine flow cycles from
three segments in MV Mouse
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Figure 20: Universality function analysis methodology. The dotted line represents a
sample average flow cycle depicting multiple flow cycles within the same animal.

The two averaged cycles were then plotted using a t/t0 time scale. A Gaussian
curve fitting method was used to find the best curve representing the average of these two
curves by optimizing the errors as shown in the black curve in Figure 21. The function
f(η) = e-0.95 η2 represents a potential universal lymphatic flow curve.
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Figure 21: Lymphatic universal flow cycle function. The blue curve represents the
average flow cycle for WT Mouse. The red curve represents the average flow cycle
for MV Mouse. The solid black curve shows a Gaussian curve fit for the two curves.

4.6 Particle Trajectory
A particle located in a valve recirculation zone, a particle travelling in the vessel
lumen and particle in contact with the valve surface were considered for a trajectory
study comparison in WT and MV. The length of time corresponding to the tracking of
these particles was one flow cycle, the same flow cycle previously selected. Wall shear
stress values were calculated whenever the particle was in contact with the wall. Figure
22 shows the trajectory of the particles and the estimated WSS. The hollow circles in the
trajectory plots represents the particle moving in the antegrade direction and the solid
dots represent retrograde travel.
The particle moving in the vessel lumen and traveling over the normal valve
surface in WT Mouse during intra-lymphangion transport traveled the most and covered
roughly 100 microns. On the other hand, displacement of similar particle in MV Mouse
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traveling over the uni-leaflet valve was roughly 15 microns. Interestingly, a particle
moving and in contact with the endothelium on the vessel wall (Blue) travelled a longer
distance than the particle in the lumen (Black) in the case of MV (Figure 22d). The WSS
was higher on both valve and vessel wall endothelium in WT Mouse in comparison to
MV Mouse potentially affecting differential gene expression in the endothelium.
The valve, both uni-leaflet and bi-leaflet, promote a fluid recirculation zone
beneath the leaflets. It was observed that particles in this region do not displace and
recirculate in form of eddies in that region. The trajectory of two such particles – one
underneath each valve was studied. It could be seen in all trajectory plots that the particle
followed the same path during flow reversal as during forward flow (Figure 22). This is
characteristic of low Reynolds number flow and lymph flow has very low Reynolds
number as detailed in Chapter 1.
The presence of a single leaflet valve affected the overall inter-lymphangion
transport of the fluid in comparison to a normal bi-leaflet valve. Localized slower
transport of lymph can affect the fluid accumulation in the upstream. If this type of
valvular is more widespread, it could potentially lead to retarded lymph transport lymphedema.
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Figure 22: Comparison of trajectories of three particles within the vessel for span of
one flow cycle. The selected particles were in recirculation zone (Red), along the
vessel wall (Blue) and traveling over the valve surface (Black). Wall shear stress
(WSS) experienced by three particles of different trajectories in WT Mouse (a) and
MV Mouse (b); Trajectory of three particles in WT Mouse (c) and MV Mouse (d).
Hollow circles represent antegrade direction whereas solid circles represent
retrograde direction of travel; (e) Trajectory of a particle within the recirculating
zone of normal bi-leaflet valve in WT Mouse; (f)Trajectory of a particle within the
recirculating zone of malformed uni-leaflet valve in MV Mouse
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4.7 Comparison of Flow Fields in a Flow Cycle
Interpolated data of the velocities was compared at five points in the cycles with
no slip condition at the vessel and valve edges. The time points were same as used in
previous studies; τ = 0.0, 0.25, 0.5, 0.75 and 1.0. Figures 23 and 24 show the velocity
vector fields in the lymphatic vessels for WT Mouse and MV Mouse respectively.
It can be observed that the flow reversal is faster in the valves than in the
lymphangions. Higher velocities are observed at the center of the vessel lumen. WT
Mouse has higher fluid velocity in comparison to MV Mouse, showing heterogeneity of
lymphatics in different animals.
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Figure 23: Vector plots depicting the flow field at various times in the flow cycle (τ =
0.0, 0.25, 0.5, 0.75, 1.0) for WT Mouse.
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Figure 24: Vector plots depicting the flow field at various times in the flow cycle (τ =
0.0, 0.25, 0.5, 0.75, 1.0) for MV Mouse
47

In Figure 24, for MV Mouse, at τ = 0.5 and 0.75, when the fluid is transported
forward towards the venous system, higher fluid flow is observed from the lymphangion
upstream of a normal valve than from the lymphangion upstream of the unileaflet valve.
This suggests the possiblity of fluid obstruction due to single leaflet valve. Also, it can be
observed that at τ = 0.5 and 0.75, higher velocities are experienced closer to the vessel
wall due to the malformed valve. Thus, affecting the stresses experienced by LECs in that
region.
WSS was computed at the segments defined previously in both WT Mouse and
MV Mouse. Figure 25 shows the values of WSS in these segments at both top surface
and bottom surfaces of the vessels. The WSS magnitude values was within 1.2 dyne/cm2.
It can be noted that the higher values of WSS was observed when the flow rate was
higher (τ = 0.5, 0.75).
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Figure 25: Vessel Wall Shear Stress (WSS) from interpolated velocity data at five
time points (τ = 0.0, 0.25, 0.5, 0.75, 1.0) in the flow cycle. (a, b) WSS calculated at top
and bottom edge of the vessel respectively in three segments for WT Mouse. Red bar
depicts the segment downstream of the normal bi-leaflet valve, gray and black bars
represent the segments at center of the lymphangions; (c, d) WSS calculated at top
and bottom edge of the vessel respectively in three segments for MV Mouse - Red
bar depicts the segment downstream of the bi-leaflet valve, green bar depicts the
segment downstream of the uni-leaflet valve and black bar represents the segment
at center of the lymphangion
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4.8 Vorticity and Strain Fields
Vorticity describes the spinning motion experienced by the lymph. Figure 26 and
27 shows the vorticity field in the vessels for WT Mouse and MV Mouse at five timepoints in the flow cycle. The positive and negative signs describe the direction of
spinning. Higher vorticity regions were observed near the valves in both WT and MV
Mice. Higher flow rate (τ = 0.5, 0.75) promote higher vorticity regions in the vessels.
Higher vorticity regions can potentially be regions for flow separation and are mostly
seen downstream of the valves.
The fluid deformation represented by normal and shear strain is represented in
Figures 28, 29, 30 and 31 for both cases. Narrowing of vessel within the valve regions
promote higher normal and shear strain fields as seen in the figures.
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Figure 26: Vorticity field within the vessel at various times in a flow cycle (τ = 0.0.
0.25. 0.5, 0.75, 1.0) for WT Mouse

51

Figure 27: Vorticity field within the vessel at various times in a flow cycle (τ = 0.0.
0.25. 0.5, 0.75, 1.0) for MV Mouse
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Figure 28: Normal strain field within the vessel at various times in a flow cycle (τ =
0.0. 0.25. 0.5, 0.75, 1.0) for WT Mouse
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Figure 29: Normal strain field within the vessel at various times in a flow cycle (τ =
0.0. 0.25. 0.5, 0.75, 1.0) for MV Mouse
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Figure 30: Shear strain field within the vessel at various times in a flow cycle (τ =
0.0. 0.25. 0.5, 0.75, 1.0) for WT Mouse
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Figure 31: Shear strain field within the vessel at various times in a flow cycle (τ =
0.0. 0.25. 0.5, 0.75, 1.0) for MV Mouse
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CHAPTER 5
CONCLUSION

This study explores the effects of a single leaflet valve in wild-type mouse
lymphatic vessels by studying the lymph transport in vivo. Presence of retrograde was
observed flow in wild-type mice models even in presence of valves. The lymphatic
system is a complex network of smaller initial and pre-collecting lymphatics and larger
collecting lymphatics. Thus, it should be noted that flow of particles was studied in just
one of these vessels among a complex network of lymphatic vessels.
Initial immunohistochemistry experiments failed to show signals for both PROX1 and eNOS. Increasing the permeabilization time helped with PROX-1 signal. This way,
the lymphatic network could be identified. However, localized expression of eNOS on
LECs was not clearly observed. This experiment can be performed to study the presence
of different protein expressions within the same vessel.
Future works include studying the flow and effects of flow in genetically
modified models. Lymphocytes can be labeled instead of injecting particles, to further
enhance our understanding of lymph transport in vivo. Also, increasing the sampling size
can help understand the effects of malformation in better way. The universality flow
function computed in this study can also be verified for by increasing the sampling size,
both looking at different mouse models and different regions within the same animal.
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